Table 1 Indirect treatment comparison between TBZ and DEU (as reported by us in Rodrigues et al. [5]), both in odds ratios as initially reported, and converted to risk differences; and as reported by Claassen et al. [1] as risk differences
Adverse event | Indirect comparison | ||
|---|---|---|---|
Rodrigues et al. [5] | Claassen et al. [1] | ||
OR (95% CI) (TBZ vs DEU) | RD (95% CI) (DEU vs TBZ) | RD (95% CI) (DEU vs TBZ) | |
SAE | 5.44 (0.09 to 322.08) | −0.07 (−0.17 to 0.03) | −0.074 (−0.167 to 0.019) |
Somnolence | 4.95 (0.34 to 72.37) | −0.21 (−0.39 to −0.03)* | −0.215 (−0.392 to −0.037)* |
Diarrhoea | 0.07 (0.03 to 2.06) | 0.12 (−0.03 to 0.27) | 0.115 (−0.038 to 0.268) |
Insomnia | 14.18 (0.47 to 426.77) | −0.24 (−0.40 to −0.04)* | −0.237 (−0.387 to −0.087)* |
Fatigue | 1.21 (0.31 to 11.14) | −0.07 (−0.26 to 0.12) | −0.067 (−0.256 to 0.123) |
Falls | 2.71 (0.31 to 23.98) | −0.07 (−0.26 to 0.12) | −0.078 (−0.265 to 0.110) |
Depression | 17.15 (0.55 to 531.90) | −0.17 (−0.31 to −0.28)* | −0.170 (−0.304 to −0.037)* |